Spots Global Cancer Trial Database for hpv vaccine
Every month we try and update this database with for hpv vaccine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine | NCT00501137 | Cervical Cancer Genital Warts | HPV (Human Papi... | 9 Years - 26 Years | University of British Columbia | |
| The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | NCT01249365 | Infections, Pap... | GSK580299 (Cerv... | 26 Years - | GlaxoSmithKline | |
| Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis | NCT00829608 | Recurrent Respi... | Human Papilloma... | 18 Years - 80 Years | University of Missouri-Columbia | |
| Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents | NCT00534638 | Infections, Pap... | Cervarix Engerix-B | 12 Years - 15 Years | GlaxoSmithKline | |
| Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females | NCT02740790 | Human Papilloma... | HPV vaccine Placebo | 9 Years - 45 Years | Shanghai Zerun Biotechnology Co.,Ltd | |
| Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making | NCT00807898 | Cervical Cancer | 13 Years - | University of Louisville | ||
| Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study | NCT00929526 | Infections, Pap... | Liquid-based cy... Blood sampling | 20 Years - 25 Years | GlaxoSmithKline | |
| Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil | NCT00524745 | Dose Schedule S... | Biological: qua... | 11 Years - 13 Years | PATH | |
| Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females | NCT02740790 | Human Papilloma... | HPV vaccine Placebo | 9 Years - 45 Years | Shanghai Zerun Biotechnology Co.,Ltd | |
| Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects | NCT00652938 | Infections, Pap... | HPV Vaccine (GS... Engerix B | 9 Years - 15 Years | GlaxoSmithKline | |
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand | NCT00849381 | Infections, Pap... | GSK580299, GSK ... | 26 Years - | GlaxoSmithKline | |
| Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital) | NCT01159834 | Human Papilloma... Infection | 10 Years - 16 Years | Barretos Cancer Hospital | ||
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand | NCT00849381 | Infections, Pap... | GSK580299, GSK ... | 26 Years - | GlaxoSmithKline | |
| Phase I Clinical Trial of a Candidate HPV Vaccine | NCT05672966 | Human Papilloma... | Human papilloma... Placebo | 18 Years - 35 Years | Wuhan BravoVax Co., Ltd. | |
| Prevalence of ENT Diseseas | NCT06105346 | Conscripts Military Induct... ENT Disease Rhinosinusitis ... Rhinosinusitis HPV Infection HPV Vaccine Long COVID ENT Surgery | 17 Years - 19 Years | Medical University of Graz | ||
| Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making | NCT00807898 | Cervical Cancer | 13 Years - | University of Louisville | ||
| Immunogenicity of Fractional Dose of the HPV Vaccines | NCT05291871 | HPV Infection HPV Vaccine | HPV vaccine | 27 Years - 45 Years | University of Washington | |
| Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects | NCT00947115 | Infections, Pap... | Blood sampling Cervico-vaginal... | 20 Years - 60 Years | GlaxoSmithKline | |
| Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females | NCT01031069 | Infections, Pap... Papillomavirus ... | GSK Biologicals... Merck's Human P... | 15 Years - 25 Years | GlaxoSmithKline | |
| Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects | NCT00652938 | Infections, Pap... | HPV Vaccine (GS... Engerix B | 9 Years - 15 Years | GlaxoSmithKline | |
| Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients With Actinic Keratosis | NCT05202860 | Actinic Keratos... Basal Cell Carc... Squamous Cell C... | HPV Vaccine PLACEBO vaccine | 18 Years - | Bispebjerg Hospital | |
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand | NCT00849381 | Infections, Pap... | GSK580299, GSK ... | 26 Years - | GlaxoSmithKline | |
| HPV and Male Homosexuality in General Practice? | NCT05078554 | Papilloma Viral... | 18 Years - 26 Years | University Hospital, Strasbourg, France | ||
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US | NCT00799825 | Infections, Pap... | GSK Biological'... | 18 Years - | GlaxoSmithKline | |
| Intradermal, Fractional Dose of HPV Vaccines: | NCT04235257 | HPV Infection HPV Vaccine | HPV vaccine | 27 Years - 45 Years | University of Washington | |
| Cancer Prevention for Young Rural Adults | NCT05618158 | Cancer | 4 Corners Rural... | 18 Years - 26 Years | Klein Buendel, Inc. | |
| Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer | NCT04096911 | Uterine Cervica... Cervical Cancer Cervical Neopla... Cervix Cancer | Sintilimab quadrivalent HP... | 18 Years - | Northern Jiangsu People's Hospital | |
| Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response | NCT03296397 | Genital Warts | Vaccination wit... Injection of No... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Phase I Clinical Trial of a Candidate HPV Vaccine | NCT05672966 | Human Papilloma... | Human papilloma... Placebo | 18 Years - 35 Years | Wuhan BravoVax Co., Ltd. | |
| Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys | NCT04711265 | HPV Vaccine HPV Infection HIV-1-infection | Quadrivalent HP... | 9 Years - 14 Years | Kenya Medical Research Institute | |
| Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors | NCT05665543 | Cancer HPV Associated ... | GLAm app | 9 Years - 26 Years | Masonic Cancer Center, University of Minnesota | |
| Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts | NCT02750202 | Genital Warts | Quadrivalent HP... Hepatitis B vac... | 16 Years - | University of Pretoria | |
| Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine | NCT01735006 | Cervical Intrae... Cervical Cancer Vaginal Intraep... Vulvar Intraepi... Persistent Infe... | HPV Vaccine HEV vaccine | 18 Years - 45 Years | Xiamen University | |
| SDH of HPV Vaccine Completion | NCT03709602 | Human Papilloma... | - | Duke University | ||
| A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls | NCT02834637 | Human Papilloma... | bivalent HPV va... nonavalent HPV ... | 9 Years - 14 Years | London School of Hygiene and Tropical Medicine | |
| Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer | NCT01909752 | Carcinoma, Non-... | Cyclophosphamid... DRibble vaccine Imiquimod GM-CSF HPV vaccine | 18 Years - | UbiVac | |
| A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine | NCT03900572 | HPV Infections | HPV Vaccine Placebo | 9 Years - 45 Years | Shanghai Zerun Biotechnology Co.,Ltd | |
| Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys | NCT04711265 | HPV Vaccine HPV Infection HIV-1-infection | Quadrivalent HP... | 9 Years - 14 Years | Kenya Medical Research Institute | |
| Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | NCT01190189 | Infections, Pap... | GSK580299 (Cerv... | 26 Years - | GlaxoSmithKline | |
| HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | NCT04432597 | HPV Positive Ca... Vulvar, Vaginal... Anal Cancer Oropharyngeal C... Cervical Cancer | PRGN-2009 (Phas... PRGN-2009 (Phas... M7824 MRI Bone scan CT scan Brain CT Brain MRI Biopsy (Phase I... Biopsy (Phase I... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination | NCT03442062 | Human Papilloma... | Assessment Feed... Physician-to-ph... Active Interven... | - | University of North Carolina, Chapel Hill | |
| Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis | NCT00829608 | Recurrent Respi... | Human Papilloma... | 18 Years - 80 Years | University of Missouri-Columbia | |
| Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study | NCT01418937 | Infections, Pap... | CervarixTM (GSK... | 26 Years - | GlaxoSmithKline | |
| Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America | NCT00546078 | Infections, Pap... | Cervarix™ | 15 Years - 25 Years | GlaxoSmithKline | |
| Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects. | NCT00877877 | Infections, Pap... Papillomavirus ... | Blood sampling | 15 Years - 24 Years | GlaxoSmithKline | |
| HPV Vaccine Immunity in High-risk Women | NCT04590521 | HPV Infection | Gardasil®, Merc... | 18 Years - 25 Years | Murdoch Childrens Research Institute | |
| Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents | NCT00534638 | Infections, Pap... | Cervarix Engerix-B | 12 Years - 15 Years | GlaxoSmithKline | |
| The Parents in Appalachia Receive Education Needed for Teen Project | NCT01901770 | Healthy Human Papilloma... | educational int... educational int... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity | NCT06137352 | HPV Infection HPV Vaccine Cervical Cancer... | Follow up | 13 Years - 14 Years | Fujian Maternity and Child Health Hospital | |
| Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination in Integrated Healthcare Delivery Systems | NCT03887793 | Human Papilloma... | VACs | - | University of North Carolina, Chapel Hill | |
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand | NCT00849381 | Infections, Pap... | GSK580299, GSK ... | 26 Years - | GlaxoSmithKline | |
| A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine | NCT00501137 | Cervical Cancer Genital Warts | HPV (Human Papi... | 9 Years - 26 Years | University of British Columbia | |
| Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities | NCT00629993 | Cervical Cancer | Academic Detail... | 18 Years - 85 Years | Columbia University | |
| Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US | NCT00799825 | Infections, Pap... | GSK Biological'... | 18 Years - | GlaxoSmithKline | |
| Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects | NCT00652938 | Infections, Pap... | HPV Vaccine (GS... Engerix B | 9 Years - 15 Years | GlaxoSmithKline | |
| Retrospective Cohort Study of the Effectiveness of the Prophylactic Vaccine Against the Human Papilloma Virus in the Prevention of Recurrence in Women Who Have Received an Excisional Therapy by HSIL / CIN. | NCT04171505 | Cervix, Dysplas... HPV Infection HPV Vaccine Cervix Lesion | HPV vaccine | 18 Years - 100 Years | Hospital San Carlos, Madrid | |
| Cancer Prevention for Young Rural Adults | NCT05618158 | Cancer | 4 Corners Rural... | 18 Years - 26 Years | Klein Buendel, Inc. | |
| Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | NCT01190189 | Infections, Pap... | GSK580299 (Cerv... | 26 Years - | GlaxoSmithKline | |
| The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years | NCT04022148 | Cancer of Cervi... Vaccinia | Gardasil | 27 Years - 45 Years | University of Fukui | |
| Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination | NCT03442062 | Human Papilloma... | Assessment Feed... Physician-to-ph... Active Interven... | - | University of North Carolina, Chapel Hill | |
| Increasing HPV Vaccination in Pediatric, Adolescent, and Young Adult (PAYA) Cancer Survivors | NCT05665543 | Cancer HPV Associated ... | GLAm app | 9 Years - 26 Years | Masonic Cancer Center, University of Minnesota |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
